Ashwagandha is having a moment. Walk into any pharmacy, health store, or scroll through any wellness brand's product page and you will find it listed as an ingredient. Stress relief. Better sleep. More energy. The claims are confident. The ingredient is ancient.

But here is what most of those products do not tell you: not all ashwagandha is the same. The clinical evidence that established ashwagandha's effects on stress, cortisol, physical performance, and sleep quality was not built on generic ashwagandha root powder or a root & leaf extract. It was built on a specific, standardised, proprietary extract called KSM-66 at a specific dose, over a specific duration.

If the product you are taking does not specify KSM-66, and does not disclose the dose, the clinical literature on ashwagandha does not apply to what is in your bottle. This distinction matters more than most brands want you to know.

What KSM-66 Is? And How It Differs From Generic Ashwagandha

KSM-66 is a branded, full-spectrum ashwagandha root extract developed by Ixoreal Biomed. It is standardised to contain a minimum of 5% withanolides - the bioactive compounds in ashwagandha responsible for its adaptogenic effects. It is produced using a proprietary extraction process that concentrates the root's active constituents without using alcohol solvents, preserving the full spectrum of the plant's natural compounds.

Generic ashwagandha root powder, by contrast, is not standardised to any specific withanolide concentration. The actual withanolide content of a generic powder can vary significantly between batches and suppliers making dose-to-effect comparisons with clinical trial data unreliable.

This standardisation is why KSM-66 has accumulated over 22 published human randomised controlled trials. Researchers can study it because it is consistent. The same extract, the same concentration, reproduced reliably across studies. This body of evidence does not exist for generic ashwagandha and cannot simply be transferred to it.

Source: Ixoreal Biomed. KSM-66 Ashwagandha Clinical Studies Summary. ksm66ashwagandha.com (accessed 2026). Individual trial citations follow below.

Generic ashwagandha on a label is not the same as KSM-66 on a label. The clinical evidence belongs to the extract, not to the plant name.

What the Clinical Trials Actually Showed

The published RCT literature on KSM-66 covers four primary outcome domains: perceived stress, serum cortisol, physical performance, and sleep quality. Below is what the key trials demonstrated.

Stress and Cortisol

A double-blind, randomised, placebo-controlled trial by Chandrasekhar et al. (2012) enrolled 64 adults with a history of chronic stress. Participants received either 300mg of KSM-66 twice daily or placebo for 60 days. The KSM-66 group showed significant reductions in scores on the Perceived Stress Scale, a validated psychometric tool, compared to placebo. Serum cortisol, measured at baseline and at 60 days, was reduced by a mean of 27.9% in the treatment group versus placebo.

Source: Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root. Indian Journal of Psychological Medicine. 2012;34(3):255-262.

Cortisol is the body's primary stress hormone, produced by the adrenal glands in response to perceived threat. Chronically elevated cortisol is associated with disrupted sleep, weight gain, immune suppression, impaired memory consolidation, and mood dysregulation. A 27.9% reduction in serum cortisol is a clinically meaningful outcome.

Energy and Physical Performance

A randomised, double-blind, placebo-controlled trial by Wankhede et al. (2015) studied 57 male subjects over eight weeks. The KSM-66 group at 300mg twice daily showed significant improvements in muscle strength, cardiorespiratory endurance measured by VO2 max, and exercise recovery compared to placebo. The mechanism proposed by the researchers relates to cortisol modulation, lower chronic cortisol allows for better anabolic response to exercise and faster recovery between sessions.

Source: Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. Journal of the International Society of Sports Nutrition. 2015;12:43.

Sleep Quality

A double-blind, randomised, placebo-controlled crossover trial by Langade et al. (2019) enrolled 60 subjects with self-reported poor sleep quality. Participants received 300mg of KSM-66 twice daily for ten weeks. The treatment group showed significant improvements in sleep onset latency, total sleep time, sleep efficiency, and scores on validated sleep quality instruments including the Pittsburgh Sleep Quality Index. Morning alertness scores also improved significantly versus placebo.

Source: Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study. Cureus. 2019;11(9):e5797.

The sleep improvement is likely downstream of cortisol normalisation. When the hypothalamic-pituitary-adrenal axis (HPA axis), the system that regulates cortisol, is dysregulated, sleep architecture is disrupted. Reducing chronic cortisol load allows the body's natural sleep-wake rhythm to reassert itself. The effect is not sedation. It is regulation.

Why Dose and Form Determine Whether Any of This Applies to You

Every trial cited above used 300mg of KSM-66 twice daily. The lowest dose at which published literature demonstrates significant cortisol reduction is 240mg per day. Below that threshold, there is no published human evidence of meaningful physiological effect.

This makes dose the single most important variable when evaluating any ashwagandha product. A supplement listing KSM-66 at 50mg is not delivering a functional dose. It is delivering brand recognition on a label.

The form matters for a different reason. KSM-66 specifically uses root extract, not root-and-leaf extract. Some cheaper ashwagandha products use a combination of root and leaf, which increases withanolide content artificially but changes the phytochemical profile significantly. The clinical studies were conducted on root extract. A root-and-leaf combination is a different ingredient, regardless of how the withanolide percentage is positioned on the label.

240mg to 600mg of KSM-66 root extract. That is the dose range the evidence supports. Anything below 240mg does not have published clinical backing.

When to Expect Results And What Consistency Delivers

Ashwagandha is not an acute intervention. It does not work within hours of a single dose. The clinical trials that showed significant cortisol reduction and stress score improvement ran for 60 days minimum. The sleep quality trial ran for ten weeks.

This is consistent with how adaptogens work biologically. The HPA axis, the cortisol regulation system, does not reset overnight. It responds to sustained input over weeks. The body needs consistent exposure to the extract to recalibrate its stress response. Missing doses frequently or stopping after two weeks is not a fair test of the ingredient.

What consistent daily use at a therapeutic dose delivers, across the published literature, is a gradual normalisation of the stress response. Not elimination of stress. That is neither possible nor the claim. What the trials showed is that the body's biochemical reaction to stressors becomes more measured. Cortisol spikes are lower. Recovery from stressful events is faster. Sleep is less disrupted. The overall baseline shifts.

This is the compounding effect of a well-dosed adaptogen taken consistently. At week two it is subtle. At week eight it is measurable. At month three it has become the body's new default which is precisely why compliance, the daily habit of taking it, is as important as the dose itself.

How This Applies to FUYL COMPLETE+

FUYL Complete+ includes KSM-66 Ashwagandha at 250mg per daily serving which is within the published therapeutic range, dosed as root extract, and standardised to a minimum of 5% withanolides. This is a deliberate formulation decision, not a coincidence of label design.

250mg sits at the lower boundary of the clinically studied range rather than the midpoint. This is an honest constraint: FUYL Complete+ is a 10g serving that covers ten functional blends, and balancing dose against serving size and taste palatability involves trade-offs. The 250mg dose has published clinical support. The claims made for it, the stress resilience and cortisol modulation, are grounded in that specific dose, at that specific extract specification.

No cognition claim is made in relation to the Ashwagandha dose in FUYL COMPLETE+. The broader cognitive wellness positioning in the formulation draws on a different ingredient stack. This is what honest formulation communication looks like, matching the claim to the dose, not the dose to the claim.

To see the full adaptogen and cognitive health related ingredient stack, visit the WHY FUYL page where every ingredient is documented.

→ Learn about the FUYL COMPLETE+ formulation at fuyl.in

References

1. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root. Indian Journal of Psychological Medicine. 2012;34(3):255-262.
2. Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. Journal of the International Society of Sports Nutrition. 2015;12:43.
3. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study. Cureus. 2019;11(9):e5797.
4. Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb Ashwagandha. Journal of Alternative and Complementary Medicine. 2014;20(12):901-908.
5. Singh N, Bhalla M, de Jager P, Gilca M. An overview on Ashwagandha: a Rasayana (rejuvenator) of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines. 2011;8(5 Suppl):208-213.

FUYL Journal  ·  Article 04  ·  fuyl.in/learn  ·  © 2026 Wholsum Wellness Technology Pvt. Ltd.